JP2024534575A5 - - Google Patents
Info
- Publication number
- JP2024534575A5 JP2024534575A5 JP2024518410A JP2024518410A JP2024534575A5 JP 2024534575 A5 JP2024534575 A5 JP 2024534575A5 JP 2024518410 A JP2024518410 A JP 2024518410A JP 2024518410 A JP2024518410 A JP 2024518410A JP 2024534575 A5 JP2024534575 A5 JP 2024534575A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- uridine
- mol
- mrna
- adenosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025171713A JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247236P | 2021-09-22 | 2021-09-22 | |
| US63/247,236 | 2021-09-22 | ||
| US202163255333P | 2021-10-13 | 2021-10-13 | |
| US63/255,333 | 2021-10-13 | ||
| US202263389679P | 2022-07-15 | 2022-07-15 | |
| US63/389,679 | 2022-07-15 | ||
| PCT/US2022/044453 WO2023049299A2 (en) | 2021-09-22 | 2022-09-22 | Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Division JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534575A JP2024534575A (ja) | 2024-09-20 |
| JP2024534575A5 true JP2024534575A5 (enExample) | 2025-10-21 |
Family
ID=85721146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518410A Pending JP2024534575A (ja) | 2021-09-22 | 2022-09-22 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240390520A1 (enExample) |
| EP (1) | EP4405470A2 (enExample) |
| JP (2) | JP2024534575A (enExample) |
| KR (2) | KR20250160515A (enExample) |
| AU (1) | AU2022349449A1 (enExample) |
| CA (1) | CA3232742A1 (enExample) |
| GB (3) | GB2628238A (enExample) |
| IL (1) | IL311607A (enExample) |
| MX (1) | MX2024003570A (enExample) |
| WO (1) | WO2023049299A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2990699A1 (en) * | 2015-06-29 | 2017-01-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| AU2019336245B2 (en) | 2018-09-07 | 2026-02-26 | Beam Therapeutics Inc. | Compositions and methods for delivering a nucleobase editing system |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| CN114040977B (zh) | 2019-01-31 | 2024-09-03 | 比姆医疗股份有限公司 | 非靶脱氨反应减低的核碱基编辑器和用于定性核碱基编辑器的测定 |
| AU2020223314A1 (en) | 2019-02-13 | 2021-08-12 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| SG11202108346WA (en) | 2019-02-13 | 2021-08-30 | Beam Therapeutics Inc | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| CN115279398B (zh) | 2019-09-27 | 2025-07-04 | 比姆医疗股份有限公司 | 治疗液态癌症的组合物和方法 |
| US12576151B2 (en) | 2020-09-25 | 2026-03-17 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| WO2025137465A1 (en) * | 2023-12-21 | 2025-06-26 | Beam Therapeutics Inc. | Base editors with modified editing windows |
| WO2025167914A1 (zh) * | 2024-02-07 | 2025-08-14 | 益杰立科新加坡有限公司 | 通过表观编辑多靶点治疗疾病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691750B2 (en) * | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| SI3250691T1 (sl) * | 2015-01-28 | 2023-10-30 | Caribou Biosciences, Inc. | Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo |
| SG10202104041PA (en) * | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
-
2022
- 2022-09-22 GB GB2405381.1A patent/GB2628238A/en active Pending
- 2022-09-22 MX MX2024003570A patent/MX2024003570A/es unknown
- 2022-09-22 JP JP2024518410A patent/JP2024534575A/ja active Pending
- 2022-09-22 WO PCT/US2022/044453 patent/WO2023049299A2/en not_active Ceased
- 2022-09-22 EP EP22873600.5A patent/EP4405470A2/en active Pending
- 2022-09-22 GB GB2509407.9A patent/GB2700667A/en active Pending
- 2022-09-22 GB GB2509406.1A patent/GB2701689A/en active Pending
- 2022-09-22 AU AU2022349449A patent/AU2022349449A1/en active Pending
- 2022-09-22 KR KR1020257035760A patent/KR20250160515A/ko active Pending
- 2022-09-22 CA CA3232742A patent/CA3232742A1/en active Pending
- 2022-09-22 KR KR1020247013385A patent/KR20240099200A/ko active Pending
- 2022-09-22 IL IL311607A patent/IL311607A/en unknown
-
2024
- 2024-03-21 US US18/611,988 patent/US20240390520A1/en active Pending
-
2025
- 2025-10-10 JP JP2025171713A patent/JP2026012737A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12251470B2 (en) | Lipid nanoparticle formulations | |
| JP7506670B2 (ja) | 脂質ナノ粒子製剤 | |
| Melamed et al. | Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery | |
| WO2023152371A1 (en) | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia | |
| JP2022530018A (ja) | 脂質ナノ粒子 | |
| JP2023507521A (ja) | シュタルガルト病の処置におけるヌクレオチド脱アミノ化のためのアンチセンスオリゴヌクレオチド | |
| JP2022523302A (ja) | アッシャー症候群の処置のためのｒｎａ編集オリゴヌクレオチド | |
| JP2025019119A (ja) | ケイ素を含有するカチオン性脂質 | |
| JP2021526804A5 (enExample) | ||
| CN117479963A (zh) | Peg脂质和脂质纳米粒子 | |
| JP2021519071A (ja) | シュードウリジン化のための核酸分子 | |
| KR20220140531A (ko) | 간 성상 세포에 대한 치료제의 지질 나노입자 전달을 위한 양이온성 지질 | |
| JP2025527583A (ja) | 脂質ナノ粒子の組成物 | |
| JP2024543000A (ja) | 操作されたｒｎａ | |
| KR20230014695A (ko) | 이작용성 분자 및 이의 사용 방법 | |
| CA3173528A1 (en) | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression | |
| EP3420093A1 (en) | Micelle based system nuclease encapsulation for in-vivo gene editing | |
| US20220288237A1 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| CN121152628A (zh) | 治疗性寡核苷酸的局部递送 | |
| AU2024365431C1 (en) | Efficient, low off-target gene editing tool | |
| AU2023265171B2 (en) | Oligonucleotide | |
| EP4716741A2 (en) | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression | |
| WO2025165840A1 (en) | Compositions and methods of treating cardiovascular disease | |
| CN118613582A (zh) | 工程化rna |